Erdafitinib-associated Subretinal Fluid in a 75-Year-Old Man With Vitreomacular Traction

Area of Science:

• Ophthalmology
• Oncology
• Pharmacology

Background:

• Fibroblast growth factor receptor (FGFR) inhibitors are vital cancer therapies.
• Ocular side effects, notably subretinal fluid (SRF), are common with FGFR inhibitors.
• Vitreomacular traction (VMT) is a potential risk factor for drug-induced SRF.

Purpose of the Study:

• To investigate the link between erdafitinib, a FGFR inhibitor, and SRF development.
• To assess the role of baseline VMT in drug-induced SRF.
• To report the clinical course and management of SRF in a patient on erdafitinib therapy.

Main Methods:

• Case report of a 75-year-old male bladder cancer patient with VMT.
• Analysis of ophthalmic examinations, optical coherence tomography (OCT), and fluorescein angiography (FA).
• Monitoring of SRF and visual acuity following erdafitinib initiation, discontinuation, and recovery.

Main Results:

• The patient developed bilateral SRF and decreased vision one month after starting erdafitinib.
• Discontinuation of erdafitinib led to gradual SRF resolution and visual acuity improvement.
• OCT confirmed complete SRF resolution with stable VMT at follow-up.

Conclusions:

• Erdafitinib can induce SRF, especially in patients with predisposing retinal conditions like VMT.
• Early recognition and drug cessation are crucial for preventing vision loss.
• Further research into mechanisms and prevention of FGFR inhibitor-induced SRF is warranted.